95 related articles for article (PubMed ID: 23795866)
1. Protein kinase C inhibitors: a patent review (2010 - present).
Sobhia ME; Grewal BK; Paul ML; Patel J; Kaur A; Haokip T; Kokkula A
Expert Opin Ther Pat; 2013 Nov; 23(11):1451-68. PubMed ID: 23795866
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase C inhibitors: a patent review (2008 - 2009).
Sobhia ME; Grewal BK; Ml SP; Patel J; Kaur A; Haokip T; Kokkula A
Expert Opin Ther Pat; 2013 Oct; 23(10):1297-315. PubMed ID: 23795914
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel class of targeted kinase inhibitors that blocks protein kinase C signaling and ameliorates retinal vascular leakage in a diabetic rat model.
Grant S; Tran P; Zhang Q; Zou A; Dinh D; Jensen J; Zhou S; Kang X; Zachwieja J; Lippincott J; Liu K; Johnson SL; Scales S; Yin C; Nukui S; Stoner C; Prasanna G; Lafontaine J; Wells P; Li H
Eur J Pharmacol; 2010 Feb; 627(1-3):16-25. PubMed ID: 19850035
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and clinical development of novel agents that target the protein kinase C family.
Serova M; Ghoul A; Benhadji KA; Cvitkovic E; Faivre S; Calvo F; Lokiec F; Raymond E
Semin Oncol; 2006 Aug; 33(4):466-78. PubMed ID: 16890801
[TBL] [Abstract][Full Text] [Related]
5. Novel N-pyrimidin-4-yl-3-amino-pyrrolo [3, 4-C] pyrazole derivatives as PKC kinase inhibitors: a patent evaluation of US2015099743 (A1).
Das J
Expert Opin Ther Pat; 2016; 26(4):523-8. PubMed ID: 26593678
[TBL] [Abstract][Full Text] [Related]
6. Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity.
Le XF; Marcelli M; McWatters A; Nan B; Mills GB; O'Brian CA; Bast RC
Oncogene; 2001 Dec; 20(57):8258-69. PubMed ID: 11781840
[TBL] [Abstract][Full Text] [Related]
7. Protease-activated receptor-2 stimulates intestinal epithelial chloride transport through activation of PLC and selective PKC isoforms.
van der Merwe JQ; Moreau F; MacNaughton WK
Am J Physiol Gastrointest Liver Physiol; 2009 Jun; 296(6):G1258-66. PubMed ID: 19359428
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase C intervention: the state of play.
Roffey J; Rosse C; Linch M; Hibbert A; McDonald NQ; Parker PJ
Curr Opin Cell Biol; 2009 Apr; 21(2):268-79. PubMed ID: 19233632
[TBL] [Abstract][Full Text] [Related]
9. Some different effect of PKC inhibitors on the acetylcholine, and endothelin-1-induced contractions of rat bronchial smooth muscle.
Sakai H; Yamamoto M; Chiba Y; Misawa M
Eur J Pharmacol; 2009 Sep; 618(1-3):58-62. PubMed ID: 19615994
[TBL] [Abstract][Full Text] [Related]
10. Current status and future prospects of C1 domain ligands as drug candidates.
Boije af Gennäs G; Talman V; Yli-Kauhaluoma J; Tuominen RK; Ekokoski E
Curr Top Med Chem; 2011; 11(11):1370-92. PubMed ID: 21513495
[TBL] [Abstract][Full Text] [Related]
11. Directed modulation of protein kinase C isozyme selectivity with bisubstrate-based inhibitors.
van Wandelen LT; van Ameijde J; Mady AS; Wammes AE; Bode A; Poot AJ; Ruijtenbeek R; Liskamp RM
ChemMedChem; 2012 Dec; 7(12):2113-21. PubMed ID: 23139239
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase C βII in diabetic complications: survey of structural, biological and computational studies.
Sobhia ME; Grewal BK; Bhat J; Rohit S; Punia V
Expert Opin Ther Targets; 2012 Mar; 16(3):325-44. PubMed ID: 22404224
[TBL] [Abstract][Full Text] [Related]
13. Reciprocal regulation of protein kinase C isoforms results in differential cellular responsiveness.
Sudan R; Srivastava N; Pandey SP; Majumdar S; Saha B
J Immunol; 2012 Mar; 188(5):2328-37. PubMed ID: 22271653
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase C isoforms in atherosclerosis: pro- or anti-inflammatory?
Fan HC; Fernández-Hernando C; Lai JH
Biochem Pharmacol; 2014 Mar; 88(2):139-49. PubMed ID: 24440741
[TBL] [Abstract][Full Text] [Related]
15. Classical PKC isoforms in cancer.
Martiny-Baron G; Fabbro D
Pharmacol Res; 2007 Jun; 55(6):477-86. PubMed ID: 17548205
[TBL] [Abstract][Full Text] [Related]
16. Structure of the catalytic domain of human protein kinase C beta II complexed with a bisindolylmaleimide inhibitor.
Grodsky N; Li Y; Bouzida D; Love R; Jensen J; Nodes B; Nonomiya J; Grant S
Biochemistry; 2006 Nov; 45(47):13970-81. PubMed ID: 17115692
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological activity of isophthalic acid derivatives targeted to the C1 domain of protein kinase C.
Boije af Gennäs G; Talman V; Aitio O; Ekokoski E; Finel M; Tuominen RK; Yli-Kauhaluoma J
J Med Chem; 2009 Jul; 52(13):3969-81. PubMed ID: 19438240
[TBL] [Abstract][Full Text] [Related]
18. Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKCtheta) inhibitors.
Cole DC; Asselin M; Brennan A; Czerwinski R; Ellingboe JW; Fitz L; Greco R; Huang X; Joseph-McCarthy D; Kelly MF; Kirisits M; Lee J; Li Y; Morgan P; Stock JR; Tsao DH; Wissner A; Yang X; Chaudhary D
J Med Chem; 2008 Oct; 51(19):5958-63. PubMed ID: 18783200
[TBL] [Abstract][Full Text] [Related]
19. Alkyl cinnamates as regulator for the C1 domain of protein kinase C isoforms.
Mamidi N; Gorai S; Sahoo J; Manna D
Chem Phys Lipids; 2012 Apr; 165(3):320-30. PubMed ID: 22414757
[TBL] [Abstract][Full Text] [Related]
20. PKC inhibitors: potential in T cell-dependent immune diseases.
Baier G; Wagner J
Curr Opin Cell Biol; 2009 Apr; 21(2):262-7. PubMed ID: 19195860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
